1. Br J Haematol. 2012 May;157(4):507-10. doi: 10.1111/j.1365-2141.2012.09039.x. 
Epub 2012 Feb 2.

Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a 
Children's Oncology Group (COG) study.

Chang BH, Willis SG, Stork L, Hunger SP, Carroll WL, Camitta BM, Winick NJ, 
Druker BJ, Schultz KR.

DOI: 10.1111/j.1365-2141.2012.09039.x
PMCID: PMC4290865
PMID: 22299775 [Indexed for MEDLINE]

Conflict of interest statement: Conflict of Interest: BHC, SGW, LS, WLC, BMC, 
NJW and KRS have no competing financial interests. SPH is a member of the 
Bristol Myers Squibb Dasatinib Pediatric Advisory Committee (without 
compensation). His children own stock in Bristol Myers Squibb. B.J.D. has 
financial interest in MolecularMD and receives clinical trial funding from 
Novartis and Bristol Myers Squibb.